United Therapeutics Corporation (NASDAQ:UTHR) Q2 2020 Earnings Conference Call July 29, 2020 9:00 AM ET
Corporate Participants
Dewey Steadman - Head, Investor Relations
Martine Rothblatt - Chairman and Chief Operating Officer
Mike Benkowitz - President and Chief Operating Officer
Leigh Peterson - Vice President, Product Development
Conference Call participants
Hartaj Singh - Oppenheimer
Eun Yang - Jefferies
Martin Auster - Credit Suisse
Liana Moussatos - Wedbush Securities
Christopher Zopf - Cowen and Company
Operator
Good morning and welcome to the United Therapeutics Corporation Second Quarter 2020 Earnings Call. My name is Marcela and I will be your conference operator today. All participants are in listen-only mode until the question-and-answer portion of this earnings call. [Operator Instructions]
I'd now like to turn the call over to Mr. Dewey Steadman, Head of Investor Relations at United Therapeutics.
Dewey Steadman
Good morning.
It's my pleasure to welcome you to the United Therapeutics Corporation Second Quarter 2020 Earnings Call. Accompanying me on today's call are Dr. Martine Rothblatt, our Chairman and Chief Executive Officer; Mr. Michael Benkowitz, our President and Chief Operating Officer; Mr. James Edgemond, our Chief Financial Officer and Treasurer; and Dr. Leigh Peterson, our Vice President of Product Development.
Remarks today will include forward-looking statements representing our expectations or beliefs regarding future events. These statements involve risks and uncertainties that may cause actual results to differ materially. Our latest SEC filings, including Form 10-K and 10-Q contain additional information on these risks and uncertainties. We assume no obligation to update our forward-looking statements.
Today's remarks may also include financial measures that were not prepared in accordance with U.S. Generally Accepted Accounting Principles or GAAP. Reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in our earnings release available on our Web site at ir.unither.com.
Today's remarks may discuss the progress and results of our clinical trials or other developments with respect to our products. These remarks are intended solely to educate investors and are not intended to serve as the basis for medical decision-making or to suggest that any products are safe and effective for any unapproved or investigational uses. All prescribing information for the products is available on our Web site.
Now, I'd like to turn the call over to Dr. Rothblatt for an overview of our second quarter financial results and business activities of United Therapeutics. Dr. Rothblatt?
